Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CMMY19113 / S1803 / Brea Lipe

Research Question:
Does treating multiple myeloma patients with two drugs Daratumumab and Lenalidomide help them become negative for the disease?

Basic Study Information

Purpose:
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.

Location: University of Rochester Medical Center
Study Reference #: CMMY19113

Lead Researcher (Principal Investigator)

Lead Researcher:  Brea Lipe

Study Contact Information

Study Coordinator: Lisa Metzger
Email: lisa_metzger@urmc.rochester.edu

Additional Study Details

Return to Search